Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 May;9(5):663-70.
doi: 10.1586/era.09.14.

Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms

Ehab Atallah  1 , Srdan Verstovsek
Affiliations
Review

Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms

Ehab Atallah et al. Expert Rev Anticancer Ther. 2009 May.

Abstract

The discovery of the Janus kinase (JAK)2 V617F mutation in patients with myeloproliferative neoplasms was a major milestone in understanding the biology of those disorders. Several groups simultaneously reported on the high incidence of this mutation in patients with myeloproliferative neoplasms: almost all patients with polycythemia vera harbor the mutation and about 50% of patients with essential thrombocythemia and primary myelofibrosis have the mutation, making the development of JAK2 tyrosine kinase inhibitors an attractive therapeutic goal. In addition, inhibition of JAK2 kinase may have a therapeutic role in other hematologic malignancies, such as chronic myeloid leukemia or lymphoma. A number of molecules that inhibit JAK2 kinase have been described in the literature, and several are being evaluated in a clinical setting. Here, we summarize current clinical experience with JAK2 inhibitors.

PubMed Disclaimer

References

    1. Liu CB, Itoh T, Arai K, Watanabe S. Constitutive activation of JAK2 confers murine interleukin-3-independent survival and proliferation of BA/F3 cells. J Biol Chem. 1999;274(10):6342–6349. - PubMed
    1. Liu RY, Fan C, Garcia R, Jove R, Zuckerman KS. Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines. Blood. 1999;93(7):2369–2379. - PubMed
    1. Takemoto S, Mulloy JC, Cereseto A, et al. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci USA. 1997;94(25):13897–13902. - PMC - PubMed
    1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054–1061. One of the first papers to describe this abnormality in patients with myeloproliferative neoplasms. - PubMed
    1. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–1148. One of the first papers to describe this abnormality in patients with myeloproliferative neoplasms. - PubMed

Website

    1. A Phase 1/2 study of oral SB1518 in subjects with chronic idiopathic myelofibrosis www.clinicaltrials.gov/ct2/show/NCT00745550?term=jak2+inhibitor&rank=3

MeSH terms